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Abstract
Background: There is currently a lack of consensus on how health-related quality of life and other patient-reported
outcome measures in cancer randomized clinical trials are analyzed and interpreted. This makes it difficult to compare
results across RCTs, synthesize scientific research, and use that evidence to inform product labeling, clinical guidelines,
and health policy. [AQ: 1]The Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of
Life Endpoints Data for Cancer Clinical Trials (SISAQOL) Consortium aims to develop guidelines and recommendations
to standardize analyses of patient-reported outcome data in cancer RCTs.
Methods and Results: Members from the SISAQOL Consortium met in January 2017 to discuss relevant issues. Data
from systematic reviews of the current state of published research in patient-reported outcomes in cancer RCTs indi-
cated a lack of clear reporting of research hypothesis and analytic strategies, and inconsistency in definitions of terms,
including ‘‘missing data,’’ ‘‘health-related quality of life,’’ and ‘‘patient-reported outcome.’’ Based on the meeting proceed-
ings, the Consortium will focus on three key priorities in the coming year: developing a taxonomy of research objectives,
identifying appropriate statistical methods to analyze patient-reported outcome data, and determining best practices to
evaluate and deal with missing data.
Conclusion: The quality of the Consortium guidelines and recommendations are informed and enhanced by the broad
Consortium membership which includes regulators, patients, clinicians, and academics.
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Background[AQ: 2]
The patients’ voice is increasingly part of the evaluation
of risks and benefits of cancer therapies. As such, data
on patient-reported outcomes (PROs) that quantify
how a patient feels and/or functions are frequently col-
lected in cancer clinical trials.1 However, the lack of
standards and clear guidelines on how these patient-
reported data should be analyzed and interpreted
diminishes their added value and makes it difficult to
compare results across different trials.2 This hinders
research findings from informing important processes
such as clinical decision-making, product labeling, clin-
ical guidelines, and health policy.3
To explore the perspectives of multiple stakeholders,
the European Organisation for Research and
Treatment of Cancer convened a multidisciplinary
international consortium focusing on ‘‘Setting
International Standards in Analyzing Patient-Reported
Outcomes and Quality of Life Endpoints Data for
Cancer Clinical Trials’’ (SISAQOL). This article sum-
marizes the Consortium’s work to date and provides a
critical backdrop for future recommendations.
Methods and results
The European Organization for Research and Treatment
of Cancer’s kick-off meeting in January 2016 solicited
attendees’ views on the need for developing standards,
guidelines, and recommendations for PRO analysis in
trials. There was a clear consensus that standards and best
practices for PRO data analysis are lacking, such guidance
is urgently needed, and a multidisciplinary team of experts
is crucial to ensure technically correct, comprehensive, and
balanced recommendations. Based on this input,
SISAQOL moved forward. A summary of this initial
meeting has been previously reported.3
The SISAQOL Consortium’s second consensus
meeting was convened a year later to discuss concrete
strategies regarding standardizing PRO analysis, with
the end goal being to produce internationally recog-
nized guidelines. Participants were leading PRO
researchers and statisticians and representatives from
international oncological and medical societies, advi-
sory and regulatory bodies, academic societies, the
pharmaceutical industry, cancer institutes, and patient
advocacy organizations (see author list).
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Perspectives
Regulators/advisory bodies. Regulators and advisors from
the European Medicines Agency network, the US
Food and Drug Administration, Health Canada, and
the Institute for Quality and Efficiency in Health Care
discussed the current role of PROs in their organiza-
tions’ decision-making processes. It was clear that these
groups recognize the importance of the patient’s experi-
ence and perspective and their added value in the
benefit-risk assessment of cancer treatment, and efforts
are underway to identify methods to best incorporate
the patient’s voice into their programs.4–7 However, it
was also evident that regulators have reservations
about the conclusions drawn from PRO data to date.
Poorly defined research objectives (and hypotheses)
and lack of rigorous standards in analyzing PRO data
in regulatory submissions have hampered the useful-
ness of such data for regulatory decision-making. To
assess the potential added value of patient-reported
data in trials, one key criterion is to establish interna-
tional standards in data analysis.
Patient. It was emphasized that throughout a patient’s
cancer journey, clear communication between the
patient and the stakeholders involved in treatment on
risks, benefits, and potential side effects is crucial.8
Patients need to be heard regarding side effects, their
feelings about their treatments, and how they are func-
tioning physically, mentally, emotionally, and socially.
Such information needs to be collected and synthesized
across patients to increase the knowledge base about
patient experiences in a way that will be useful for
future patients. Identifying the best ways to involve
patients and survivors in initiatives such as SISAQOL,
which focus primarily on technical research issues, is
challenging. The discussion of missing PRO data pro-
vided a clear opportunity for possible patient participa-
tion. Missing data is a critical issue in any trial as
missing data present difficulties in analysis and drawing
robust conclusions about treatments. Minimizing
avoidable missing assessments is critical. While
researchers have identified many factors that contribute
to avoidable missing data, patients themselves generate
PRO data, and SISAQOL provides an opportunity to
work with patients to get their ideas about how to
minimize the amount of avoidable missing PRO data
in clinical trials9 and to communicate the importance
of providing complete data.10
Literature. Five systematic reviews provided a summary
of the current quality of hypothesis reporting and anal-
ysis of PRO data in published trials in locally advanced
and metastatic breast cancer,11 advanced non-small cell
lung cancer,12 small cell lung cancer,13 as well as two
reviews on methods for dealing with missing data.14,15
For the purposes of this report, three key findings from
these reviews are highlighted.
Hypothesis. Clear research objectives and a priori
hypotheses are needed prior to statistical analysis.
Otherwise, statistical analyses are exploratory, and no
conclusions can be drawn. In the systematic reviews for
metastatic breast11 and advanced non-small cell lung
cancers,12 findings showed that only 7% of the articles
(metastatic breast: 4 of 58 articles; advanced non-small
cell lung cancer: 2 of 27 articles) reported specific a
priori PRO research hypothesis. In a systematic review
evaluating the quality of PRO reporting in trials pub-
lished between 2002 and 2008, only around 50% of the
794 trials reported a PRO hypothesis.16,17 These find-
ings imply that although PRO data are being included
in trials, statistical analyses are often being conducted
without clear reported PRO research objectives and
hypotheses. This causes uncertainty regarding whether
the results reported are based on (a) a priori hypotheses
with an a priori statistical analysis plan that allow con-
clusions to be drawn or (b) exploratory analyses
intended to generate future hypotheses, but where find-
ings from this trial remain inconclusive.
Statistical methods. In the three systematic reviews,
preliminary findings showed that at least 10 different sta-
tistical methods were used to evaluate PRO data.11–13
This is a problem, since the variety of statistical tech-
niques employed makes it challenging not only to com-
pare findings across trials but also to build on previous
work to make the results more generalizable and conclu-
sive. Another problem is the failure to correct for type 1
error (or alpha adjustment) for multiple testing. This
problem is particularly relevant for PRO data due to the
possibility of calculating scores for an entire measure,
subdomains, and/or at a range of time points. If mul-
tiple scales and/or assessment points are tested inde-
pendently from one another, and the alpha level is not
adjusted for multiple testing (e.g. it remains at 0.05
for each of the tests), the probability of observing at
least one significant result simply due to chance is
inflated. This then leads to findings that are difficult
to interpret. This was a limitation found in this litera-
ture. For all three reviews,11–13 less than 40% of the
articles controlled for type 1 error when it was needed
(metastatic breast cancer: 40%, 23 of 58 articles;
advanced non-small cell lung cancer: 4%, 1 of 27 arti-
cles; small cell lung cancer: 27%, 9 of 33 articles).
Missing data. Missing data is a common problem in
PRO analysis in trials. How missing data are considered
in analysis, especially when the amount of missing data
is substantial, may bias the analysis and critically influ-
ence the conclusions that can be drawn. For this reason,
reports need to specify the analytic approach used to
address missing data.18,19 In the systematic reviews for
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metastatic breast cancer11 and advanced non-small cell
lung cancer,12 only 24% (14 of 58 articles) and 19% (5
of 27 articles) of the articles, respectively, reported how
the analysis addressed missing data. Furthermore, the
statistical methods across reports ranged from simple
imputation (e.g. last observation carried forward) to
model-based methods (e.g. pattern mixture modeling).
These findings demonstrate the lack of standardization
on how to handle missing PRO data.
Implications
Developing hypothesis. The systematic reviews show a
lack of clearly reported research hypotheses. New
guidelines for protocol development (i.e. SPIRIT
PRO)20,21 and PRO reporting (i.e. CONSORT-PRO)16
also recognize this issue. It was proposed that three
components are necessary to specify in an a priori
research hypothesis, specifically,
 The domains of interest,
 How the reference arm is expected to behave within
the time frame of interest, and
 How the treatment arm is expected to behave rela-
tive to the reference arm.
A rationale and evidence-based arguments informed
by clinical and patient experience are needed to support
these components of the hypothesis. To address stan-
dardized classification of such hypotheses, the
Consortium agreed to develop a taxonomy of PRO
objectives, including underlying assumptions. This tax-
onomy has the potential not only to help researchers to
be more precise in hypotheses in protocols but also to
allow comparison of objectives and findings across
trials. The taxonomy is currently under development.
Statistical methods. The systematic reviews11–13 demon-
strate that the current trials literature does not provide
a good foundation to determine which statistical
method is recommended for a specific research objec-
tive. Not only is there a lack of clearly reported
research objectives, but there is also no consensus on
which statistical methods to use. Rather than recom-
mending a specific statistical method, it was agreed that
a more useful approach is to define essential statistical
properties for analyzing PRO data. For example, an
important statistical property is adjusting for covari-
ates. Covariate adjustment is a common practice in
trials for stratification, controlling for potential imbal-
ance between treatment arms, or improving precision
of the treatment effect (especially when the covariate
has an important influence on the outcome).22,23 The
Consortium will compile a systematic list of statistical
properties, with a recognition of the importance of bal-
ancing feasibility and accuracy. Following consensus
on identifying essential statistical properties, the
Consortium will determine statistical methods that fit
these criteria, which can then be matched with research
objectives identified in the previously mentioned taxon-
omy. SISAQOL also emphasized the importance of
developing criteria for descriptive statistics (including
visualization) that can provide more complete docu-
mentation of patient reports. For example, it is com-
mon practice to report the mean (or median) levels of a
PRO measure per treatment arm over time. However,
although this summary statistic may be useful, it is not
sufficient to use it alone. Rather, this should be accom-
panied by a measure of variability to provide an indica-
tion of the diversity of responses. For example, an
average score of ‘‘3’’ in a possible range of scores from
1 to 5 could mean that all participants reported a ‘‘3’’
or that half of the participants reported ‘‘1’’ and the
other half reported a ‘‘5.’’ A measure of variability can
capture this difference, whereas the average would not.
SISAQOL Consortium members will work toward
developing guidelines to standardize descriptive analy-
ses and visualization approaches across all trials.
Missing data. Before undertaking statistical analysis, the
researcher needs to be certain that the dataset is valid
for analysis. Guidelines often indicate that a substantial
amount of missing data can invalidate any analysis.18
The Consortium questioned the definition of substan-
tial, given that this is not consistent in the literature.
The Institute for Quality and Efficiency in Health Care
standard approach (e.g. Regofaranib24) is to consider
valid any analysis from a dataset that includes baseline
data with at least one follow-up from at least 70% of
patients. However, this criterion is not used consistently
across the literature. Different definitions of missing
data and their calculation may lead to varying practices
and results and call out for guidelines. It is not cur-
rently clear if it will be possible for international con-
sensus on a fixed threshold that defines an acceptable
percentage of missing data. For example, in a hypothe-
tical situation where 65% of PRO data are missing,
some investigators would agree that drawing conclu-
sions on treatment efficacy based on these patient
reports would be futile. However, others may argue
that analyzing the 35% of patients for whom data are
available could be useful to understand more about
patient well-being in this subgroup, although generali-
zation to the larger trial population would not be possi-
ble. Exploring the potential to identify a fixed threshold
for an acceptable percentage of missing data to have a
valid analysis and robust findings is a priority question
for the SISAQOL Consortium. Another SISAQOL
goal is to develop and validate a set of macros, an auto-
mated way to systematically examine missing data pat-
terns and the impact of different imputation methods
on findings. An initial pilot test of macros developed by
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the Mayo Clinic team was performed on a Mayo trial
dataset. Capabilities of these macros include producing
percentages of missing values over time and providing
more detailed information on missing data patterns.
Moreover, these macros also implement and test the
effects of several imputation methods, which could then
be used for sensitivity analysis. The macros (or others)
may prove useful following further testing and valida-
tion with other clinical trial datasets and guidelines on
the appropriate use, and interpretation of findings from
these missing data macros are needed.
Terminology. An evidence-based review on the history
on terminology of patient-reported indicators (such as
quality of life, health-related quality of life, and PRO)
in the context of cancer and trials demonstrate the rela-
tively recent emergence of terms (see Table 1). Indeed,
widespread consensus on the exact meaning of these
terms is not yet set, and new terminologies continue to
surface: for example, patient-generated health data,
patient experience, and patient-centered outcome.
Currently, definitions have been offered by regulatory
bodies5,6 and academic societies (e.g. International
Society for Quality of Life Research25). Although not
all definitions are the same, health-related quality of life
is generally seen as a subcategory within the broader
PRO construct, which may include other patient-
reported variables. Currently, as seen in Table 1, the
most citations and research information are based on
‘‘quality of life’’ and ‘‘health-related quality of life’’ end-
points than for the broader ‘‘PRO’’ concept. It is not
within the remit of the Consortium to find consensus
on these non-statistical terminologies. Regardless of the
terminology used, Consortium members cited likely
considerable overlap in data analytic approaches for all
PROs, given that all come from the same source (the
cancer patient).
Conclusion
Based on discussions and evidence extracted from sys-
tematic reviews of published literature, the SISAQOL
Consortium has confirmed the priority need to develop
guidelines and standards in analyzing PRO data in
trials. The Consortium is focusing on three key priori-
ties: developing a taxonomy of research objectives,
identifying appropriate statistical methods to analyze
PRO data, and determining how best to evaluate and
deal with missing data. SISAQOL’s work will provide
a toolbox for analysis of PRO outcomes in trials that is
urgently needed and will advance the international
research agenda now and into the future.
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